清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial

医学 临床终点 人口 风湿病 内科学 安慰剂 结缔组织病 类风湿性关节炎 免疫学 胃肠病学 自身免疫性疾病 随机对照试验 疾病 病理 替代医学 环境卫生
作者
E. William St. Clair,Alan N. Baer,Wan‐Fai Ng,Ghaith Noaiseh,Chiara Baldini,Teresa K. Tarrant,Athena Papas,Valérie Devauchelle‐Pensec,Liangwei Wang,Wenjing Xu,Tuyet‐Hang Pham,Keith A. Sikora,William A. Rees,Ilias Alevizos
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:30 (6): 1583-1592 被引量:106
标识
DOI:10.1038/s41591-024-03009-3
摘要

Sjögren's disease (SjD) is a chronic, systemic autoimmune disease with no approved disease-modifying therapies. Dazodalibep (DAZ), a novel nonantibody fusion protein, is a CD40 ligand antagonist that blocks costimulatory signals between T and B cells and antigen-presenting cells, and therefore may suppress the wide spectrum of cellular and humoral responses that drive autoimmunity in SjD. This study was a phase 2, randomized, double-blinded, placebo (PBO)-controlled trial of DAZ with a crossover stage in two distinct populations of participants with SjD. Population 1 had moderate-to-severe systemic disease activity and population 2 had an unacceptable symptom burden and limited systemic organ involvement. All participants had a diagnosis of SjD, with 21.6% and 10.1% having an associated connective tissue disease (rheumatoid arthritis or systemic lupus erythematosus) in populations 1 and 2, respectively. The remaining participants would be considered as having primary Sjögren's syndrome. The primary endpoint for population 1 (n = 74) was the change from baseline in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index at day 169. The primary endpoint for population 2 (n = 109) was the change from baseline in the European League Against Rheumatism Sjögren's Syndrome Patient Reported Index at day 169. The primary endpoints (least squares mean ± standard error) were achieved with statistical significance for both population 1 (DAZ, -6.3 ± 0.6; PBO, -4.1 ± 0.6; P = 0.0167) and population 2 (DAZ, -1.8 ± 0.2; PBO, -0.5 ± 0.2; P = 0.0002). DAZ was generally safe and well tolerated. Among the most frequently reported adverse events were COVID-19, diarrhea, headache, nasopharyngitis, upper respiratory tract infection, arthralgia, constipation and urinary tract infection. In summary, DAZ appears to be a potential new therapy for SjD and its efficacy implies an important role for the CD40/CD40 ligand pathway in its pathogenesis. ClinicalTrials.gov identifier: NCT04129164 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
忧郁凝阳完成签到,获得积分10
2秒前
整齐成协完成签到,获得积分10
7秒前
15秒前
冥土追魂完成签到,获得积分10
16秒前
冥土追魂发布了新的文献求助10
19秒前
丘比特的应助被武雨寒采纳,获得10
30秒前
懵懂的小之完成签到,获得积分10
30秒前
专注的怜珊完成签到,获得积分10
32秒前
完美世界的应助被武雨寒采纳,获得10
37秒前
科研通AI6.4的应助被cat采纳,获得10
42秒前
45秒前
羞涩的傲菡完成签到,获得积分10
46秒前
武雨寒发布了新的文献求助10
48秒前
兴奋乞完成签到,获得积分10
1分钟前
零度空间完成签到,获得积分10
1分钟前
痴情的不惜完成签到,获得积分10
1分钟前
1分钟前
整齐念薇完成签到,获得积分10
1分钟前
武雨寒发布了新的文献求助10
1分钟前
1分钟前
诸葛平卉完成签到 ,获得积分10
1分钟前
星辰大海的应助被psm采纳,获得10
1分钟前
1分钟前
飞天大南瓜完成签到,获得积分10
1分钟前
Gilgardea发布了新的文献求助10
1分钟前
车车完成签到 ,获得积分10
1分钟前
精明开山完成签到,获得积分10
1分钟前
1分钟前
鲤鱼遥完成签到,获得积分10
1分钟前
cat发布了新的文献求助10
2分钟前
AG完成签到,获得积分10
2分钟前
田田完成签到 ,获得积分10
2分钟前
2分钟前
等待凡英完成签到,获得积分10
2分钟前
陈荆洲完成签到,获得积分10
2分钟前
高高的玉兰完成签到,获得积分10
2分钟前
2分钟前
小二郎的应助被cat采纳,获得10
2分钟前
科研通AI6.2的应助被pitinmoon采纳,获得10
2分钟前
漂亮秋荷完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166413
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750478
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473835